Project Grant HT9425261E030
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $397,788 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2029. The award supports research activities focused on "Targeting Age-Driven Metastatic Vulnerabilities in Triple-Negative Breast Cancer," to be conducted at the center's Tampa, Florida location....
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $798,673 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2025, with an ultimate completion date of June 14, 2029. The award funds research to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. This research aims to advance understanding of metastatic mechanisms...
- Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,124,896 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2025, for a four-year performance period concluding July 14, 2029. The award funds research characterizing the role of aberrant FGD1 (FYVE, RhoGEF and PH Domains-containing Protein 1) splicing in brain and bone metastasis in clear cell renal cell...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $968,875 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025, through June 30, 2028. The award funds research to identify and assess immunotherapy targets in neurofibromatosis type 2 (NF2)-associated schwannomatosis, a rare genetic disorder characterized by the development of multiple...
- Summary of Federal Cooperative Agreement Award H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $18.7 million Cooperative Agreement from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 1, 2025, with a completion date of August 31, 2029. The award funds a four-year research initiative focused on developing and evaluating combinatorial therapies utilizing dendritic cell therapies to...
- The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
- The Defense Health Agency awarded H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. $842,500 under the Military Medical Research and Development federal grant program (CFDA 12.420) to define the glycoproteome in melanoma progression from June 1, 2023 to May 31, 2026. Through this award, Moffitt Cancer Center will investigate medical solutions for melanoma on the battlefield by defining the glycoproteome, which are glycosylated RNA and proteins, and how their expression changes...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $459,360 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on genetic risk factors associated with prostate cancer in self-identified Black veterans. The three-year award, which commenced July 1, 2025 and concludes June 30, 2028, supports hypothesis-driven biomedical research aimed at advancing...
- Project Grant Summary: Impact of Tertiary Lymphoid Structures in Oncolytic Virus-Induced Tumor Elimination H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. was awarded $1.685 million under the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) for a three-year project performance period from August 1, 2025, through July 31, 2028. This Project Grant supports advanced biomedical research investigating the role of tertiary lymphoid structures...